Why should one attend EASD 2019?
How can new technologies help improve life of people with diabetes?
What challenges remain with regards to diabetes education?
Have technological advances in insulin delivery and glucose monitoring lowered the burden of hypoglycemia?
Other than technological improvements, what other aspects are key to success in reducing the risk of hypoglycemia events?
Is there an established link between hypoglycemia and an increased risk of cardiovascular events and mortality?
In terms of cardiovascular risk, as a cardiologist, what do you think should the diabetologist be looking for and when should the patient be referred?
Does type 2 diabetes cause more harm to the cardiovascular system than type 1 diabetes?
What simple things should a non-diabetologist look for when they see a patient with diabetes?
What novel diabetes subgroups have been identified and how do these relate to outcomes?
Should these diabetes subgroups be treated differently?
Is the existence of multiple subtypes of diabetes a debatable subject?
Have any novel genetic markers emerged that might aid in diagnosis and management of diabetes?
What are the implications of the DUAL VIII trial?
What novel oral peptide treatments have emerged for type 2 diabetes in recent years?
What new insulin formulations are being investigated? How do these differ from more traditional formulations?
The diabetic brain: culprit or victim?
What proportion of patients with type 2 diabetes have diabetic neuropathy and how serious a problem is it in real-life?
What are some of the most common misconceptions about diabetic neuropathy and what measures are being taken so that it is recognized early and treated adequately?
What are some of the current unmet needs in treatment of diabetic neuropathy and how can these be overcome?
SGLT2 inhibitors are now a well-established therapy in patients with type 2 diabetes. What is the evidence for their use in patients with type 1 diabetes?
Do SGLT2 inhibitors represent the future in type 1 diabetes?
Is the risk of ketoacidosis worrisome with the use of SGLT2 inhibitors in type 1 diabetes?
What impact does exercise have on vascular health in patients with type 2 diabetes?
Can current European guidelines on prevention of diabetes be considered adequate in reducing the burden of disease?
Do new glucose lowering drugs have any impact on quality of life?
What are the main take home messages from cardiovascular outcomes trials in diabetes?
What has been learned from renal outcome studies in diabetes?
How should the way we currently treat diabetes change?
What are some of the “hot topics” of the 2019 EASD Meeting?
What is the importance of the EASD Annual Meeting?
What are some of the opportunities offered today by artificial intelligence?
What is the Blue Index and how can it help in management of diabetes?
What is the current scenario on the use of GLP1-RAs in South Asia?
Is continuous glucose monitoring of benefit to patients in a real-world scenario?